- Home
- CREV vs AYTU Comparison
CREV vs AYTU Comparison
Compare CREV & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- AYTU
- Stock Information
- Founded
- CREV 2007
- AYTU N/A
- Country
- CREV Ireland
- AYTU United States
- Employees
- CREV N/A
- AYTU N/A
- Industry
- CREV
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- CREV
- AYTU Health Care
- Exchange
- CREV Nasdaq
- AYTU Nasdaq
- Market Cap
- CREV 7.2M
- AYTU 8.3M
- IPO Year
- CREV N/A
- AYTU N/A
- Fundamental
- Price
- CREV $3.66
- AYTU $1.35
- Analyst Decision
- CREV Strong Buy
- AYTU
- Analyst Count
- CREV 1
- AYTU 0
- Target Price
- CREV $39.00
- AYTU N/A
- AVG Volume (30 Days)
- CREV 322.8K
- AYTU 30.9K
- Earning Date
- CREV 01-01-0001
- AYTU 02-12-2025
- Dividend Yield
- CREV N/A
- AYTU N/A
- EPS Growth
- CREV N/A
- AYTU N/A
- EPS
- CREV N/A
- AYTU N/A
- Revenue
- CREV $39,261,077.00
- AYTU $77,232,000.00
- Revenue This Year
- CREV $40.76
- AYTU N/A
- Revenue Next Year
- CREV $86.18
- AYTU N/A
- P/E Ratio
- CREV N/A
- AYTU N/A
- Revenue Growth
- CREV 41.52
- AYTU N/A
- 52 Week Low
- CREV $2.00
- AYTU $1.30
- 52 Week High
- CREV $22.34
- AYTU $3.45
- Technical
- Relative Strength Index (RSI)
- CREV 44.01
- AYTU 32.11
- Support Level
- CREV $3.39
- AYTU $1.35
- Resistance Level
- CREV $4.41
- AYTU $1.44
- Average True Range (ATR)
- CREV 0.39
- AYTU 0.10
- MACD
- CREV -0.02
- AYTU -0.02
- Stochastic Oscillator
- CREV 26.18
- AYTU 2.63
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.